Parkman Healthcare Partners LLC Cuts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Parkman Healthcare Partners LLC lessened its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 53.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 216,881 shares of the biotechnology company's stock after selling 247,167 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.10% of BioCryst Pharmaceuticals worth $1,631,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BCRX. Vanguard Group Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company's stock worth $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of BioCryst Pharmaceuticals by 25.1% in the fourth quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company's stock worth $438,000 after buying an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after buying an additional 91,998 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $80,000. Finally, Choreo LLC purchased a new position in shares of BioCryst Pharmaceuticals in the fourth quarter worth approximately $106,000. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 0.8%

BioCryst Pharmaceuticals stock traded up $0.08 during midday trading on Monday, reaching $10.32. The stock had a trading volume of 1,754,123 shares, compared to its average volume of 3,004,346. BioCryst Pharmaceuticals, Inc. has a 52-week low of $5.92 and a 52-week high of $11.11. The firm has a market cap of $2.16 billion, a price-to-earnings ratio of -16.91 and a beta of 1.08. The company has a fifty day moving average of $8.11 and a 200 day moving average of $7.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. During the same period in the previous year, the company earned $0.28 earnings per share. The business's quarterly revenue was up 40.8% on a year-over-year basis. Equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Analyst Upgrades and Downgrades

BCRX has been the subject of a number of recent analyst reports. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the stock a "buy" rating in a research report on Tuesday, May 6th. Royal Bank of Canada reiterated an "outperform" rating and issued a $13.00 price target (up from $11.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. upped their price target on shares of BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the stock an "overweight" rating in a research report on Tuesday, May 6th. Cantor Fitzgerald initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $20.00 price target for the company. Finally, Wedbush initiated coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.